Heart drug showdown: which protects the right ventricle better after valve surgery?
NCT ID NCT07416331
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two drugs, levosimendan and dobutamine, in 52 adults undergoing heart valve replacement. The goal was to see which one better preserves right ventricular function after surgery. Patients were randomly assigned to receive one of the drugs, and their heart function was measured using echocardiograms at several time points.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- levosimendan and dobutamine
- What this could lead to
- If one drug proves better, it could become the preferred choice to protect heart function during valve surgery.
- What could go wrong
- This is a small, single-center study with only 52 patients, so results may not apply to everyone. The drugs also have known side effects like low blood pressure or heart rhythm issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Helwan University
Giza, 12566, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scoliosis's hidden toll: can we predict lung and heart risks?
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Which breathing setting keeps Kids' lungs healthier during heart surgery?
- Could a simple sleep guide ease insomnia in lung disease?
- Could a gut bacteria transplant ease a rare lung disease?
- A Needle-Free heart check? MRI may replace invasive catheterization